Innovation

Three looks at how AI may change retinal practice

Artificial intelligence models have shown the potential to decrease disparities in diabetic eye care, personalize management for nAMD treatment and predict outcomes for CRVO.

Pipeline Report: New entries continue to exceed exits

Exits for discontinued programs (three over two years) exceed exits for approvals (two).

Why not vitrectomy for vitreous opacities?

Why pars plana vitrectomy has come of age for vitreous opacities in selected patients.

The robots are coming to retina

An update of the science behind robotic-assisted vitreoretinal surgery and its potential future applications.

Two tales of DR progression

Clinical trials show encouraging outcomes for treating diabetic retinopathy progression, but the real-world evidence tells a different story.

Five things to know about biosimilars in retina

A primer on the review and approval processes as the first anti-VEGF biosimilar prepares for launch in 2022.

Mixed results in DME, PDR hemorrhage, ROP

Five abstracts on gene therapy and role of central subfield thickness in diabetic macular edema, vitreous hemorrhage and retinopathy of prematurity.

Retinal implant platforms moving from uveitis to AMD

Treatments show potential for various posterior-segment diseases based on their success treating noninfectious uveitis.

Five emerging treatments show mixed results

Uncertainty about PVL for VMT and aflibercept for NPDR, some clarity on PDT, and early promise for stem cells and a bioresorbable implant.

Ocular gene therapy: The next generation

Emerging viral and synthetic vectors along with newer delivery platforms are poised to broaden genetic treatments in retina.